Kura Oncology (KURA) Tax Provisions (2025 - 2026)
Kura Oncology (KURA) posted quarterly Tax Provisions of $8000.0 for Q1 2026, down 96.46% year-over-year from $226000.0 in Q1 2025, and down 88.73% quarter-over-quarter from $71000.0 in Q4 2025.
Kura Oncology (KURA) Tax Provisions (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Tax Provisions for 2 consecutive years, with $8000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions fell 96.46% year-over-year to $8000.0; the TTM figure through Mar 2026 stood at $79000.0 (changed N/A YoY), while the FY2025 annual figure was $297000.0, up 3.48% from the prior year.
- Tax Provisions eased to $8000.0 in Q1 2026 per KURA's latest filing, from $71000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $226000.0 in Q1 2025 and bottomed at $8000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Dec 31, 2025 | 71,000.00 |
| Mar 31, 2025 | 226,000.00 |